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Uroporphyrinogen decarboxylase activity was investigated in cultures of chick embryo liver by two 
different methods: (1) analysis of porphyrin composition following incubation of intact cells with 6- 
aminolevulinic acid; and (2) a more conventional direct enzymic assay of cell homogenates. Activity was 
detectibly decreased following exposure of cells to 100 ng/ml 2,4,5,3~4’-pentabromobiphenyl using the 
first method, but not the second. This decrease in activity was reversed by homogenizing the cells treated 
with 100 ng/ml pentabromobiphenyl. It is concluded that the direct homogenate assay of the enzyme may 
miss or underestimate decreases in its in vivo activity. 
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I. INTRODUCTION 
Activity of uroporphyrinogen decarboxylase 
(EC 4.1-l .37) (URO-D) is decreased in liver homo- 
genates from animals treated for several weeks 
with hexachlorobenzene [l] or 2,3,7,8-tetrachloro- 
p-dibenzodioxin (21. The activity is also decreased 
in humans with the liver disease, porphyria cuta- 
nea tarda (PCT) (see ref. in [3]). Both the chemi- 
cally induced porphyria and PCT are characterized 
by similar patterns of porphyrin accumulation and 
excretion (see reviews [4,5]). 
workers have shown specific effects on URO-D in 
the culture by planar congeners of polychlorinated 
biphenyls [8,9] and have investigated some aspects 
of the mechanism [IO]. 
In all these studies, accumulation of uroporphy- 
rin (URO) by intact hepatocytes incubated with 6- 
aminolevuIinate (ALA) has been used as an indica- 
tor of decreased URO-D activity [6- 101. However, 
this accumulation of URO, with or without prior 
incubation with ALA, has not been correlated with 
direct measurements of URO-D activity on cell ho- 
mogenates using a conventional enzyme assay. 
Chick embryo liver cells in culture have been re- We now report that low concentrations of 
ported to exhibit an apparent decrease in activity 2,4,5,3 ’ ,4’ -pentabromobiphenyl (PBB) decrease 
of URO-D after treatment for only one day with URO-D activity in intact cells assayed by incubati- 
some polyhalogenated hydrocarbons [6]. We have on with ALA. This concentration of PBB is much 
recently extended these studies using various con- lower than that required to decrease URO-D activi- 
geners of polybrominated biphenyls [7]. Other ty assayed directly in homogenates. 
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2. MATERIALS AND METHODS 
2,4,5,3’ ,4’-PBB was isolated from Firemaster, 
a mixture of polybrominated biphenyIs by Drs G. 
Dannan and S.. Aust, Michigan State University. 
Porphyrin standards were from Porphyrin Pro- 
ducts (Logan, UT). PBB was added to cultures in 
dimethylsulfaxide (2 pi/ml). Synthetic pentacar- 
boxylporphyrin III and URO III were gifts from 
Dr A. Jackson, University College, Cardiff. 
Chick embryo hepatocyte cultures were prepa- 
red and maintained as in [l l]. URO, protoporphy- 
rin (PROTO) and coproporphyrin (COPRO) in 
cultures and homogenates were determined by the 
spectro~uo~ometric method in fl2] after extrac- 
tion with an equal volume of 0.5 N perchloric acid 
in methanol Porphyrin composition was dso de- 
termined by thin-layer chromatography 1133 and 
by high pressure liquid chromatography (WPLC) 
[14]. Cells and medium from IO-cm diam, dishes 
were lyophilized separately before preparation of 
methyl esters of the porphyrins [13]. URO-D was 
assayed in homogenates as described using either 
pentacarboxyporphyrinogen III or uroparphyrin- 
ogen III fl.5]. 
3. RESULTS 
Figure I shows the dose-response curves for the 
effect of PBB on URO-D activity using either 
porphyrin formation from ALA by intact cells 
(fig.la) or the rate of decarboxylation of penta- 
Fig. 1. Decreased activity of uroporphyrinogen 
decarboxylase after exposure of cultured hepatocytes to 
2,4,5,3’ ,4’-pentabromobipheny~ (PB3). (a) Porphyrin 
composition after exposure of intact cells to ALA. 
Cultures were prepared in &cm diam dishes as 
described in section 2 and exposed to PBB for 20 h. To 
one set of cultures, DES (l~~g~rnl) was then added. 
After 4 h of further incubation, 150 @I ALA was added 
and porphyrin composition determined after 90 min of 
further incubation, Each point is the mean of triplicate 
dishes (values agreed within 10%). (0) FBB only; (A) 
PBB and ALA; (a) PBB, DES and ALA. (b) Rate of 
decarboxylation of pentacarboxyporphyrinogen 111 by 
homogenates of cultured hepatocytes. Homogenates 
were prepared after 20 h PBB treatment and enzyme 
activity determined as in section 2. Each point is the 
mean 2 SD for 3 separate dishes. Results from the two 
separate experiments are shown (o,LI). 
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carboxyporphyrinogen III by cell homogenates 
(fig.lb), as indicators of URO-D activity. Intact 
cells exposed to PBB produced more URO and less 
PROTO when incubated with ALA than did con- 
trol cells (fig. la). Addition of desferrioxamine 
(DES), a powerful iron chelator, to prevent forma- 
tion of heme from PROTO, had no effect on URO 
accumulation but enhanced PROTO formation at 
all concentrations of PBB. These results show that 
PROTO formation is progressively inhibited by 
PBB at concentrations from 100-1000 ng/ml. The 
inhibition is accompanied by accumulation of 
URO, but not COPRO (fig.la), suggesting that 
these changes are produced by progressive inhibi- 
tion of URO-D activity. 
In contrast, measurement of URO-D activity in 
homogenates howed no decrease in activity until 
a concentration of 500 ng PBB/mI was reached 
(fig. lb) by which concentration the intact cells ac- 
cumulated porphyrin (shown by HPLC to be 
mainly URO and heptacarboxylic porphyrin). Al- 
most identical results were obtained when uro- 
porphyrinogen III was used as substrate, thus ex- 
cluding the possibility that PBB selectively decrea- 
ses the decarboxylation of pentacarboxy- 
porphyrinogen. A similar dose-response curve 
was obtained when cultured cells were sonicated 
before incubation with ALA (fig.2). Again, there 
was no evidence for a decrease in URO-D activity 
at 100 ng PBB/ml. 
The cellular and medium porphyrins in cultures 
treated with PBB and then incubated with ALA 
(fig. la) were fractionated by thin-layer chromato- 
graphy. The patterns were similar at 100 ng 
PBB/ml and 1000 ng PBB/ml for both cells and 
medium. Cells contained mainly URO (58% type 
III isomer at 100 ng/ml; 42% at 1000 ng/ml) and 
heptacarboxylic porphyrin (100% type III isomer; 
accounting for 23% and 17% of the total porphy- 
rin at IO0 ng/ml and 1000 ng/ml, respectively). At 
both concentrations, the medium contained URO 
and porphyrins with 7 to 4 carboxyl groups, inclu- 
ding a porphyrin of the isocoproporphyrin series, 
and PROTO. URO and 7-carboxylporphyrin was 
almost entirely retained within the cells as reported 
originally [16] and recently confirmed [9]. 
4. DISCUSSION 
Previously, it has been shown only by indirect 
0e05 hOPRO 
0.1 r URO 
I @ +DES 
, I I 
100 500 1000 
2$,5,@P B B kg/ml) 
Fig.2. Composition of porph~ins generated from ALA 
by sonicates of cultures treated with 
2,4,5,3’,4’-pentabromobiphenyl. Cultures were 
prepared as described in section 2 in IO-cm diam. dishes. 
Cultures were exposed to PBB for 20 h and then rinsed 
with saline, harvested in 1.1 ml 50 mM Tris (0.25 M 
sucrose) 1 mM ALA (pH 7.4) at 4’C, sonicated and 
0.2 ml incubated at 37°C for 90 min with (m---e) and 
without (o---Q) DES (0.75 mg/ml). Porphyrin 
composition was determined as described in section 2, 
and was corrected for porphyrin present before 
incubation of sonicates. 
methods that the activity of URO-D is apparently 
decreased after exposure of chick embryo cultured 
hepatocytes to several different polyhalogenated 
aromatic hydrocarbons [6-IO]. We have now 
shown that the decrease in URO-D is also detected 
in homogenates of the cells by the more conventio- 
nal direct assay used previously to measure URO- 
D in homogenates of mammalian liver (fig. lb) 
11,3,15]. The decrease in URO-D, when determi- 
ned by direct measurement in cell homogenates 
(fig. 1 b), occurred at PBB concentrations that cau- 
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sed URO accumulation by the cultures in the ab- 
sence of added ALA (fig.la). Such a relationship 
between URO-D activity and hepatic porphyrin 
concentration has been observed in the experimen- 
tal porphyrias caused by halogenated hydrocar- 
bons in rodents [1,17]. 
An unexpected finding was that loading intact 
hepatocytes with ALA caused increased URO and 
decreased PROTO accumulation at a PBB concen- 
tration (100 ng/mI) which was much lower than 
that required to produce either a decrease in URO- 
D activity, when assayed in cell homogenates, or 
an accumulation of porphyrin in the absence of 
ALA (fig. 1). The pattern of porphyrin production 
from ALA by intact cells after treatment with 
100 ng PBB/ml closely resembled the patterns 
found with 1000 ng/ml and those which accompa- 
ny decreased hepatic URO-D in intact animals and 
humans with PCT [1,4,5]. The cells treated with 
PBB retained most of the porphyrin (mainly 
URO), as does intact liver. The composition of me- 
dium porphyrins resembled that of the excreted 
porphyrins (urine and feces) of the intact animal. 
These similarities suggest hat ALA loading unco- 
vers a URO-D defect in the intact cells at 100 ng 
PBB/ml. This decrease in URO-D in the intact 
cells after treatment with 100 ng PBB/ml was re- 
versible by breaking the cells as detected by com- 
position of porphyrins accumulated from ALA 
(fig.2). 
Two possible explanations for differences bet- 
ween the dose-response curves of intact cells and 
homogenates are: (I) that there is a small decrease 
in activity of URO-D (perhaps less than 10%) that 
is not detected by the homogenate assays; (2) that 
there is inhibition of URO-D in the intact cells 
(perhaps as much as 50~0~ that is relieved when the 
cells are broken. A major difficulty in comparing 
the dose-response curves is that the ALA loading 
technique does not give the % decrease in URO-D 
in the intact cells directly. However, if one assumes 
that DES prevented conversion of PROTO to 
heme, then the amount of PROTO accumulated in 
the presence of DES (fig.la) provides an estimate 
of the relative decrease in URO-D. A 50% decrease 
in PROTO was caused by 100 ng PBB/ml and 500 
and 1000 ng PBBlml caused further decrease in 
PROTO. 
Nevertheless, we cannot rule out the second ex- 
planation, i.e., decreased URO-D inhibition upon 
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cell breakage and dilution. One might postulate 
two phases of the inhibition, a reversible one at 
IO0 ng PBB/ml and an irreversible one at 1000 ng 
PBB/ml. This explanation is consistent with a me- 
tabolite of PBB inhibiting URO-D [6,10] and dis- 
sociation of the metabolite from the enzyme upon 
dilution. Currently there are few data in favor of 
the metabolite mechanism of URO-D inhibition. 
Furthermore, very rapid change in porphyrin accu- 
mulation from PROTO to URO in cells treated 
with 3,4,3’,4’-tetrachlorobiphenyl has been repor- 
ted in [9], a finding we have reproduced (unpub- 
lished). Any inhibitory metabolite would have to 
have been very rapidly produced. 
Our results show that direct homogenate assays 
of URO-D may not reflect in vivo activity of the 
enzyme. Thus, in animals treated for long periods 
with halogenated hydrocarbons [l], URO-D may 
have been decreased earlier than detected by the 
homogenate assay. Similarly, in human PCT, 
where an approximate 40% decrease in hepatic 
URO-D is detected in homogenates (e.g., [lS]), it 
is possible that the degree of decrease is greater and 
that small decreases in URO-D activity may have 
been missed by exclusive use of the homogenate 
assay. 
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